Expert Interview
Examining Entasis Therapeutics' sulbactam-durlobactam (SUL-DUR) in treating patients with hospital acquired and ventilator-associated bacterial pneumonia ahead of the FDA PDFUA
Ticker(s): ETTX, INVAInstitution: Emory University
- Assistant Professor of Medicine at Emory University specializing in infectious disease and critical care medicine
- Manages 5-10 patients a week with invasive fungal infections.
- Research focus in nosocomial infections, antibiotic stewardship, infection control, and pulmonary disorders
How many patients with hospital acquired bacterial pneumonia and ventilator-associated bacterial pneumonia do you manage?
Added By: dami_adminOn a scale of 1-10 (10 being the most excited), how would you rate your excitement for SUL-DUR?
Added By: dami_adminAn advisory committee voted 12 to nothing to approve this drug, was that surprising, and is this likely to be approved?
Added By: catalin_adminSince 2019, we've had ceftolozane, ceftazidime, avibactam, imipenem, vaborbactam, cefiderocol, and now we have sulbactam and durlobactam. What do you think is going to be the best practice?
On combination of sulbactam and durlobactam, tested in the ATTACK trial comparing against Colistin. What did you think about the results in that trial? What's your high-level view on what that demonstrated?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
